Clinical Trials & Patents
FK506 (Tacrolimus) in Pulmonary Arterial Hypertension The trial is completed and does not include any patients.
Rationale: Mutations in bone morphogenetic protein receptor 2 (BMPR2) are present in >80% of familial and ~20% of sporadic pulmonary arterial hypertension (PAH) patients. Furthermore dysfunctional BMP signaling is a general feature of pulmonary hypertension even in non-familial PAH.
We have discovered that FK506 increases BMPR2 signaling and reverses experimental pulmonary hypertension.
“United States Patent 61481317 Low dose FK506 for the treatment of Pulmonary Arterial Hypertension”
Leland Stanford Junior University
Phil Beachy, PhD
David Solow-Cordero, PhD
Marlene Rabinovitch, MD
Edda Spiekerkoetter, MD